STAAR Surgical Company experienced a sharp revenue decline of nearly 24% in fiscal 2025 alongside significant operating losses, influenced in part by growing R&D expenses and disrupted operational momentum. The collapsed Alcon merger deal dealt a blow to anticipated synergies and strategic direction but did not impair the company’s regulatory progress evidenced by FDA approval expanding EVO ICL patient age eligibility to 60 years. Leadership transitions in early 2026 have installed interim co-CEOs from within senior management, aiming to stabilize execution. Strong liquidity with a 4.55 current ratio supports continued investment, though near-term profitability remains elusive. The coming quarters will require close monitoring of revenue recovery post-FDA expansion and cash flow dynamics amid persistent regulatory and competitive challenges.